【News】CEJ Fund announced to invest in Kringle Pharma, Inc.

Cybernics Excellence Japan Fund 1 Investment Limited Partnership (“CEJ Fund”), operated by CYBERDYNE’s subsidiary CEJ Capital, Inc. announced to invest in Kringle Pharma, Inc. (“Kringle Pharma”), a company that develops pharmaceutical products based on HGF (Hepatocyte growth factor). Kringle Pharma, Inc. intends to utilize the investment to prepare and conduct phase III trials for patients with acute spinal cord injury.

Link to the press release by Kringle Pharma:
https://www.kringle-pharma.com/wp-content/uploads/2020/03/200302_Financing_1st_ver4.pdf

Past Press Release by CYBERDYNE (2016/12/05):
https://www.cyberdyne.jp/english/company/PressReleases_detail.html?id=5158